NVO•benzinga•
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Summary
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga